Use of Rosuvastatin in HIV-Infected Subjects to Modulate Cardiovascular Risks

NCT01218802 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

147

Enrollment

OTHER

Sponsor class

Conditions

HIV Infections
Heart Disease

Interventions

DRUG: Rosuvastatin 10 mg. daily for 96 weeks
DRUG: Placebo

Sponsor

University Hospitals Cleveland Medical Center

Collaborators

[object Object]
[object Object]